Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

CIMZIA® is associated with a BOXED WARNING regarding serious infections and malignancy and important WARNINGS AND PRECAUTIONS, including heart failure, anaphylaxis, or serious allergic reactions, hepatitis B virus reaction, demyelinating disease, cytopenius, or pancytopenia, and Lupus-like syndrome.

This material is not for distribution or reproduction.